SS30 could impair the function of CD123 molecule by competing with IL-3 to bind to CD123, and could down-regulate the expression of p-AKT and p-STAT5, resulting in inhibitory effect on CD123+ AML tumor cells in vitro and in vivo. Here, IL3 is linked to neoplasm.